NYSE:FNA - New York Stock Exchange, Inc. - US69913P1057 - Common Stock - Currency: USD
13.09
0 (0%)
The current stock price of FNA is 13.09 USD. In the past month the price increased by 0.46%. In the past year, price increased by 33.57%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.17 | 225.27B | ||
ISRG | INTUITIVE SURGICAL INC | 63.89 | 167.79B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.28 | 138.41B | ||
SYK | STRYKER CORP | 27.86 | 129.62B | ||
MDT | MEDTRONIC PLC | 15.32 | 104.91B | ||
BDX | BECTON DICKINSON AND CO | 14.13 | 56.45B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.41 | 40.68B | ||
IDXX | IDEXX LABORATORIES INC | 36.15 | 32.95B | ||
RMD | RESMED INC | 23.85 | 30.97B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 13.47 | 27.69B | ||
DXCM | DEXCOM INC | 40.07 | 25.92B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 14.83 | 21.89B |
Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. The company is headquartered in Englewood, Colorado and currently employs 525 full-time employees. The company went IPO on 2021-10-21. The firm provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. The company has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.
PARAGON 28 INC
14445 Grasslands Drive
Englewood COLORADO US
Employees: 574
Company Website: https://paragon28.com/
Investor Relations: https://ir.paragon28.com/
Phone: 17209121332
The current stock price of FNA is 13.09 USD.
The exchange symbol of PARAGON 28 INC is FNA and it is listed on the New York Stock Exchange, Inc. exchange.
FNA stock is listed on the New York Stock Exchange, Inc. exchange.
10 analysts have analysed FNA and the average price target is 14.28 USD. This implies a price increase of 9.09% is expected in the next year compared to the current price of 13.09. Check the PARAGON 28 INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PARAGON 28 INC (FNA) has a market capitalization of 1.10B USD. This makes FNA a Small Cap stock.
PARAGON 28 INC (FNA) currently has 574 employees.
PARAGON 28 INC (FNA) has a support level at 13.03 and a resistance level at 13.1. Check the full technical report for a detailed analysis of FNA support and resistance levels.
The Revenue of PARAGON 28 INC (FNA) is expected to grow by 14.16% in the next year. Check the estimates tab for more information on the FNA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FNA does not pay a dividend.
PARAGON 28 INC (FNA) will report earnings on 2025-05-08, after the market close.
PARAGON 28 INC (FNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
The outstanding short interest for PARAGON 28 INC (FNA) is 2.52% of its float. Check the ownership tab for more information on the FNA short interest.
ChartMill assigns a technical rating of 8 / 10 to FNA. When comparing the yearly performance of all stocks, FNA is one of the better performing stocks in the market, outperforming 94.48% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to FNA. The financial health of FNA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months FNA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS decreased by -10.53% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -18.79% | ||
ROE | -41.84% | ||
Debt/Equity | 0.84 |
ChartMill assigns a Buy % Consensus number of 72% to FNA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 25.22% and a revenue growth 14.16% for FNA